This study adds to the growing body of medical literature that suggests Celebrex and other similar drugs, also known as COX-2 inhibitors, may yield negative outcomes for patients seeking to curb the risk of colorectal cancer.
For this study, researchers recruited 1,561 individuals with a history of colorectal cancer. More than half of the subjects received Celebrex for three years before researchers were forced to stop the study due to concerns about cardiovascular complications. The researchers obtained consent from half of the original study group, which continued to receive Celebrex.
Results from the study showed over the five-year study period, Celebrex subjects were less likely to develop polyps that could lead to colorectal cancer compared to placebo subjects. However, Celebrex users faced a 66 percent higher risk of developing serious cardiac conditions.
Read the study about the advantages and disadvantages of Celebrex.
Related Articles on Polyps:
New Colonoscopy Benefit Complicating GI Collection Efforts
Study Links Physician Fatigue to Inaccurate Colonoscopy Reads
10 Recent Gastroenterology Studies Making Headlines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.